Stock Track | Omnicell Plunges 5.39% in Pre-Market as Q4 Earnings Disappoint Despite Revenue Beat

Stock Track

02-06

Omnicell Inc. (OMCL) shares plummeted 5.39% in pre-market trading on Thursday, following the company's mixed fourth quarter 2024 results reported after the market close on Wednesday.

For the quarter ended December 31, 2024, the medication management solutions provider posted earnings of $0.34 per share, missing the consensus estimate of $0.57 per share. However, revenue came in at $306.9 million, surpassing analysts' expectations of $296.9 million.

While Omnicell delivered strong revenue growth of 19% year-over-year, driven by improved macroeconomic conditions and timing of XT Series system implementations, higher costs weighed on profitability. The company cited increased expenses related to investments in generative AI, autonomous driving technologies, and other growth initiatives.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1191708832"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1191708832\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1191708832?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-06 21:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191708832","market":"us","top_or_hot":-1,"title":"Stock Track | Omnicell Plunges 5.39% in Pre-Market as Q4 Earnings Disappoint Despite Revenue Beat","media":"Stock Track","content":"<p>Omnicell Inc. (OMCL) shares plummeted 5.39% in pre-market trading on Thursday, following the company's mixed fourth quarter 2024 results reported after the market close on Wednesday.</p>\n\n<p>For the quarter ended December 31, 2024, the medication management solutions provider posted earnings of $0.34 per share, missing the consensus estimate of $0.57 per share. However, revenue came in at $306.9 million, surpassing analysts' expectations of $296.9 million.</p>\n\n<p>While Omnicell delivered strong revenue growth of 19% year-over-year, driven by improved macroeconomic conditions and timing of XT Series system implementations, higher costs weighed on profitability. The company cited increased expenses related to investments in generative AI, autonomous driving technologies, and other growth initiatives.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Omnicell Plunges 5.39% in Pre-Market as Q4 Earnings Disappoint Despite Revenue Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Omnicell Plunges 5.39% in Pre-Market as Q4 Earnings Disappoint Despite Revenue Beat\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-02-06 21:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Omnicell Inc. (OMCL) shares plummeted 5.39% in pre-market trading on Thursday, following the company's mixed fourth quarter 2024 results reported after the market close on Wednesday.</p>\n\n<p>For the quarter ended December 31, 2024, the medication management solutions provider posted earnings of $0.34 per share, missing the consensus estimate of $0.57 per share. However, revenue came in at $306.9 million, surpassing analysts' expectations of $296.9 million.</p>\n\n<p>While Omnicell delivered strong revenue growth of 19% year-over-year, driven by improved macroeconomic conditions and timing of XT Series system implementations, higher costs weighed on profitability. The company cited increased expenses related to investments in generative AI, autonomous driving technologies, and other growth initiatives.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OMCL","symbol_name":"Omnicell","start_time":0,"source_url":"","article_id":"1191708832","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191708832","pubTimestamp":1738849486,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Omnicell Inc.  shares plummeted 5.39% in pre-market trading on Thursday, following the company's mixed fourth quarter 2024 results reported after the market close on Wednesday.For the quarter ended December 31, 2024, the medication management solutions provider posted earnings of $0.34 per share, missing the consensus estimate of $0.57 per share. However, revenue came in at $306.9 million, surpassing analysts' expectations of $296.9 million.While Omnicell delivered strong revenue growth of 19% y","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OMCL":"Omnicell"},"translate_title":"尽管营收超出预期，但第四季度盈利令人失望，Omnicell盘前暴跌5.39%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMCL":1},"content_text":"Omnicell Inc. (OMCL) shares plummeted 5.39% in pre-market trading on Thursday, following the company's mixed fourth quarter 2024 results reported after the market close on Wednesday.\nFor the quarter ended December 31, 2024, the medication management solutions provider posted earnings of $0.34 per share, missing the consensus estimate of $0.57 per share. However, revenue came in at $306.9 million, surpassing analysts' expectations of $296.9 million.\nWhile Omnicell delivered strong revenue growth of 19% year-over-year, driven by improved macroeconomic conditions and timing of XT Series system implementations, higher costs weighed on profitability. The company cited increased expenses related to investments in generative AI, autonomous driving technologies, and other growth initiatives.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}